Endothelial Protein C Receptor

Introduction

The protein C anticoagulant pathway plays a critical role in the negative regulation of the blood clotting response. The pathway is triggered by thrombin, which allows the system to serve as an “on-demand” mechanism for limiting the coagulation response to injury. Specifically, the magnitude of the anticoagulant response is proportional to the level of thrombin generated.¹ The clinical importance of the pathway is illustrated by the severe thrombotic complications associated with deficiencies of members of the pathway.^2-4

The protein C pathway is initiated when thrombin binds to thrombomodulin (TM)⁵ (Fig. 1). The surface of the endothelium constitutes the main site for protein C activation. The thrombin-TM complex is a potent activator of protein C, but it has little or no ability to activate platelets or clot fibrinogen. Therefore, TM serves as a molecular switch for thrombin, including thrombin’s macromolecular specificity and physiological function. Protein C activation is enhanced when protein C binds to the endothelial cell protein C receptor (EPCR).⁶ Endothelial cell protein C receptor augments protein C activation by increasing the affinity of the thrombin-TM complex for protein C.^6-8 Not all protein C activation complexes involve EPCR since the levels of this protein are low in the microcirculation.⁹

The thrombin-TM complex is rapidly inactivated by the protein C inhibitor¹⁰ and antithrombin¹¹ (Fig. 1, bottom). Once activated protein C (APC) is formed, it proteolytically inactivates two critical blood clotting cofactors, factors Va and VIIIa,^12,13 thereby limiting further thrombin formation. Activated protein C inactivates factor Va by cleaving at Arg506, which results in rapid but incomplete loss of activity, and Arg306.¹² Cleavage at Arg306 results in complete inactivation of factor Va.

Protein S serves as a cofactor for this process by increasing the affinity of APC for the membrane surface^14-16 and by changing the specificity of the proteolytic cleavage of factor Va, which enhances cleavage at Arg306 without significantly modulating cleavage at Arg506.¹⁷ In addition, protein S blocks the ability of factor Xa to protect factor Va from inactivation by APC and has a similar function in the inactivation of the factor IXa-factor VIIIa complex.¹⁷ Furthermore, in combination with factor V, protein S enhances the ability of APC to inactivate factor VIII^18,19 (Fig. 1, middle). Recently, there have been advances in understanding how protein S accomplishes these functions.

Specifically, when protein S binds to APC, the distance from the active site of APC to the membrane surface is decreased about 1 nm.²⁰ This decrease in distance is probably responsible for the ability of protein S to selectively increase the cleavage rate at Arg306. This conclusion is based on the observation that a protein C chimera has been prepared that, in the absence of protein S, has a distance between the membrane surface and its active site similar to that of the protein S-APC complex.²¹ With the chimera, protein S influences neither the distance to membrane surface nor the rate of cleavage of Arg306 in factor Va. Furthermore, the rate of cleavage at Arg306 for the chimera and the protein S-APC complex are almost identical.²¹

Unlike most serine proteases, APC is resistant to inhibition by plasma proteinase inhibitors and circulates with a half-life of approximately 15 minutes.²² The half-life is determined by inhibition with the following plasma protease inhibitors: α₁-antitrypsin,²³ protein C inhibitor,²⁴ and α₂-macroglobulin²⁵ (Fig. 1, bottom). Each contributes to APC inhibition.

The clinical importance of this pathway is evident by the life-threatening thrombotic complications observed in infants with complete deficiencies of protein S or protein C.² In the case of total protein C deficiency, these thrombotic complications are most commonly manifested as microvascular thrombosis of the skin (purpura fulminans). These lesions can be prevented by infusion of protein C, but they reappear if the protein C levels in the patient are allowed to decrease to low levels. Heterozygous deficiencies of protein C and protein S are more common with the frequency of protein C deficiency, occurring in 1 in 300 individuals.^3,4 Heterozygous deficiencies of protein C or protein S alone are modest risk factors for thrombosis. In combination with other risk factors, however, these deficiencies substantially increase thrombotic risk.^3,4

The most common known risk factor for venous thrombosis, APC resistance, is also linked to the protein C pathway. Activated protein C normally inactivates factor Va by first cleaving at Arg506, followed by cleaving at Arg306.^12,17,26 The most common basis for APC resistance is a dimorphism in factor V, which results in replacement of Arg506 with Gln. This substitution renders this bond resistant to cleavage by APC.²⁷ This form of factor V is also termed factor V Leiden, because the molecular basis of the defect was identified in that city.²⁸ As a result of the mutation, factor V Leiden inactivation requires cleavage at Arg306, which is a relatively slow process. Fortunately, as mentioned previously, protein S stimulates cleavage at Arg306.¹⁷ This observation may account for one of the reasons that protein S deficiency in combination with factor V Leiden results in a substantial increase in risk of thrombosis. Deficiencies in the protein C activation complex, most specifically TM, could also contribute to thrombotic risk. Recently, Öhlin et al identified mutations and polymorphisms in TM that appear to be associated with increased risk of myocardial infarction or venous thrombosis.^29,30 Ireland et al³¹ identified alterations in the 5’ regulatory region of the TM gene in 5 of 104 patients with myocardial infarction. These mutations presumably reduce TM expression and contribute to the risk of myocardial infarction.³¹ Only 1 of 104 control, age matched individuals had any of these mutations. Mutations of TM also can lead to thrombosis in mice.³² Taken together, these observations provide a firm clinical basis to conclude that the members of this pathway are critical to adequate negative regulation of the blood clotting system.

• References

• 1 Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest. 1993; 92: 2003-2012.
• 2 Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med. 1995; 5: 141-148.
• 3 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: part 1. Thromb Haemost. 1996; 76: 651-662.
• 4 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: part 2. Thromb Haemost. 1996; 76: 824-834.
• 5 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989; 264: 4743-4746.
• 6 Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA. 1996; 93: 10212-10216.
• 7 Xu J, Esmon NL, Esmon CT. Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. J Biol Chem.. In press.
• 8 Fukudome K, Ye X, Tsuneyoshi N, Tokunaga O, Sugawara K, Mizokami H, Kimoto M. Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor. J Exp Med. 1998; 187: 1029-1035.
• 9 Laszik Z, Mitro A, Taylor Jr. FB, Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation. 1997; 96: 3633-3640.
• 10 Rezaie AR, Cooper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem. 1995; 270: 25336-25339.
• 11 Bourin MC, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J. 1993; 289: 313-330.
• 12 Egan JO, Kalafatis M, Mann KG. The effect of Arg306->Ala and Arg506->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Protein Sci. 1997; 6: 2016-2027.
• 13 Regan LM, Lamphear BJ, Huggins CF, Walker FJ, Fay PJ. Factor IXa protects factor VIIIa from activated protein C. J Biol Chem. 1994; 269: 9445-9452.
• 14 Harris KW, Esmon CT. Protein S is required for bovine platelets to support activated protein C binding and activity. J Biol Chem. 1985; 260: 2007-2010.
• 15 Walker FJ. Regulation of activated protein C by a new protein: a role for bovine protein S. J Biol Chem. 1980; 255: 5521-5524.
• 16 Smirnov MD, Safa O, Regan L, Mather T, Stearns-Kurosawa DJ, Kurosawa S, Rezaie AR, Esmon NL, Esmon CT. A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity. J Biol Chem. 1998; 273: 9031-9040.
• 17 Rosing J, Hoekema L, Nicolaes GAF, Thomassen MCLGD, Hemker HC, Varadi K, Schwarz HP, Tans G. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor Va^R506Q by activated protein C. J Biol Chem. 1995; 270: 27852-27858.
• 18 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem. 1994; 269: 18735-18738.
• 19 Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87: 4708-4717.
• 20 Yegneswaran S, Wood GM, Esmon CT, Johnson AE. Protein S alters the active site location of activated protein C above the membrane surface. J Biol Chem. 1997; 272: 25013-25021.
• 21 Yegneswaran S, Smirnov MD, Safa O, Esmon NL, Esmon CT, Johnson AE. Relocation of the active site of activated protein C closer to the membrane surface coincides with an increase in factor Va inactivation activity and an insensitivity to protein S stimulation of activity. J Biol Chem.. In press.
• 22 Okajima K, Koga S, Kaji M, Inoue M, Nakagaki T, Funatsu A, Okabe H, Takatsuki K, Aoki N. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost. 1990; 63: 48-53.
• 23 Heeb MJ, Griffin JH. Physiologic inhibition of human activated protein C by α₁-antitrypsin. J Biol Chem. 1988; 263: 11613-11616.
• 24 Suzuki K, Deyashiki Y, Nishioka J, Kurachi K, Akira M, Yamamoto S, Hashimoto S. Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily. J Biol Chem. 1987; 262: 611-616.
• 25 Scully MF, Toh CH, Hoogendoorn H, Manuel RP, Nesheim ME, Solymoss S, Giles AR. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, α₁-antitrypsin and α₂-macroglobulin, in patients with disseminated intravascular coagulation. Thromb Haemost. 1993; 69: 448-453.
• 26 Mann KG, Hockin MF, Begin KJ, Kalafatis M. Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. J Biol Chem. 1997; 272: 20678-20683.
• 27 Dahlback B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest. 1994; 94: 923-927.
• 28 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
• 29 Öhlin A-K, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 1995; 85: 330-336.
• 30 Norlund L, Holm J, Zoller B, Öhlin A-K. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost. 1997; 77: 248-251.
• 31 Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations in myocardial infarction. Circulation. 1997; 96: 15-18.
• 32 Weiler-Guettler H, Christie PD, Beeler DL, Healy AM, Hancock WW, Rayburn H, Edelberg JM, Rosenberg RD. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest. 1998; 101: 1983-1991.
• 33 Powars DR, Rogers ZR, Patch MJ, McGehee WG, Francis RB. Purpura fulminans in meningococcemia: association with acquired deficiencies of proteins C and S (letter). N Engl J Med. 1987; 317: 571-574.
• 34 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA. 1981; 78: 2249-2252.
• 35 Snow TR, Deal MT, Dickey DT, Esmon CT. Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation. 1991; 84: 293-299.
• 36 Hyde E, Wetmore H, Gurewich V. Isolation and characterization of an in vivo thrombin-induced anticoagulant activity. Scand J Haematol. 1974; 13: 121
• 37 Comp PC, Jacocks RM, Ferrell GL, Esmon CT. Activation of protein C in vivo. J Clin Invest. 1982; 70: 127-134.
• 38 Beller-Todd BK, Archer LT, Hinshaw LB. Recovery from endotoxin shock after extracorporeal perfusion without anticoagulation. Circ Shock. 1997; 6: 261-269.
• 39 Murphy TL, Walker FJ, Taylor Jr. FB, Beller-Todd BK, Archer LT, Sofer SS, Hinshaw LB. Endogenous anticoagulation during extracorporeal perfusion: generation of a heparin-like inhibitor. Am J Physiol. 1980; 239: H742-H750
• 40 Hinshaw LB, Chang ACK, Beller-Todd BK, Archer LT, Taylor Jr. FB. Extracorporeal perfusion without exogenous anticoagulation: its protective role in endotoxin shock. Circ Shock. 1982; 9: 281-295.
• 41 Taylor Jr. FB, Chang A, Hinshaw LB, Esmon CT, Archer LT, Beller BK. A model for thrombin protection against endotoxin. Thromb Res. 1984; 36: 177-185.
• 42 Taylor Jr. FB, Chang A, Esmon CT, D’Angelo A, Vigano-D’Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. J Clin Invest. 1987; 79: 918-925.
• 43 Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest. 1984; 74: 2082-2088.
• 44 Dahlback B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost. 1991; 66: 49-61.
• 45 Taylor F, Chang A, Ferrell G, Mather T, Catlett R, Blick K, Esmon CT. C4b-binding protein exacerbates the host response to Escherichia coli. . Blood. 1991; 78: 357-363.
• 46 Smith OP, White B, Vaughan D, Rafferty M, Claffey L, Lyons B, Casey W. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet. 1997; 350: 1590-1593.
• 47 D’Angelo A, Vigano-D’Angelo S, Esmon CT, Comp PC. Acquired deficiencies of protein S: protein S activity during oral anticoagulation, in liver disease and in disseminated intravascular coagulation. J Clin Invest. 1988; 81: 1445-1454.
• 48 Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73: 159-165.
• 49 Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol. 1988; 8: 5588-5592.
• 50 Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor α: comparison of transcriptional and posttranscriptional mechanisms. Blood 1991; 77: 543-550.
• 51 Maruyama I, Soejima Y, Osame M, Ito T, Ogawa K, Yamamoto S, Dittman WA, Saito H. Increased expression of thrombomodulin on the cultured human umbilical vein endothelial cells and mouse hemangioma cells by cyclic AMP. Thromb Res. 1991; 61: 301-310.
• 52 Yu K, Morioka H, Fritze LMS, Beeler DL, Jackman RW, Rosenberg RD. Transcriptional regulation of the thrombomodulin gene. J Biol Chem. 1992; 267: 23237-23247.
• 53 Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin-1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc Natl Acad Sci USA. 1986; 83: 3460-3464.
• 54 Hirokawa K, Aoki N. Regulatory mechanisms for thrombomodulin expression in human umbilical vein endothelial cells in vitro. J Cell Physiol. 1991; 147: 157-165.
• 55 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest. 1987; 79: 124-130.
• 56 Boehme MWJ, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W, Nawroth PP. Release of thrombomodulin from endothelial cells by concerted action of TNF-α and neutrophils: in vivo and in vitro studies. Immunology. 1996; 87: 134-140.
• 57 Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-2029.
• 58 Ohdama S, Matsubara O, Aoki N. Plasma thrombomodulin in Wegener’s granulomatosis as an indicator of vascular injuries. Chest. 1994; 106: 666-671.
• 59 Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, van Deventer SJH, Wouter ten Cate J. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost. 1995; 73: 15-20.
• 60 Okajima K, Imamura H, Koga S, Inoue M, Takatsuki K, Aoki N. Treatment of patients with disseminated intravascular coagulation by protein C. Am J Hematol. 1990; 33: 277-278.
• 61 Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, Tchernia G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med. 1991; 325: 1565-1568.
• 62 Gerson WT, Dickerman JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics. 1993; 91: 418-422.
• 63 Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr. 1995; 126: 646-652.
• 64 Rintala E, Seppala O-P, Kotilainen P, Rasi V. Protein C in the treatment of coagulopathy in meningococcal disease. Lancet. 1996; 347: 1767
• 65 Rintala E, Seppala O-P, Kotilainen P, Pettila V, Rasi V. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med. 1998; 26: 965-968.
• 66 Hancock WW, Tsuchida A, Hau H, Thomson NM, Salem HH. The anticoagulants protein C and protein S display potent anti-inflammatory and immunosuppressive effects relevant to transplant biology and therapy. Transplant Proc. 1992; 24: 2302-2303.
• 67 Fukudome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem. 1994; 269: 26486-26491.
• 68 McDonald JF, Shah AM, Schwalbe RA, Kisiel W, Dahlback B, Nelsestuen GL. Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry. 1997; 36: 5120-5127.
• 69 Regan LM, Mollica JS, Rezaie AR, Esmon CT. The interaction between the endothelial cell protein C receptor and protein C is dictated by the Gla domain of protein C. J Biol Chem. 1997; 272: 26279-26284.
• 70 Regan LM, Stearns-Kurosawa DJ, Kurosawa S, Mollica J, Fukudome K, Esmon CT. The endothelial cell protein C receptor: inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. J Biol Chem. 1996; 271: 17499-17503.
• 71 Ding W, Gu J-M, Fukudome K, Laszik Z, Grammas P, Esmon CT. Upregulation of the message for rodent endothelial cell protein C receptor (EPCR) by endotoxin and thrombin. Circulation. 1996; 94: I694 Abstract.
• 72 Xu J, Qu D, Esmon CT. Characterization of endothelial protein C receptor. In: Book of Abstracts, Vascular Biology ‘98 Scientific Conference of American Heart Association and North American Vascular Biology Organization. 1998: 61 Abstract.
• 73 Xu J, Qu D, Esmon CT. Thrombin enhanced release of soluble EPCR mediated by metalloproteinases associated with caveolae. In: Book of Abstracts, Vascular Biology ‘98 Scientific Conference of American Heart Association and North American Vascular Biology Organization. 1998: 62 Abstract.
• 74 Kurosawa S, Stearns-Kurosawa DJ, Hidari N, Esmon CT. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest. 1997; 100: 411-418.
• 75 Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D’Angelo A, Esmon CT. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes (letter). Blood 1998; 91: 724-728.
• 76 D’Angelo A, Valle PD, Crippa L, Pattarini E, Grimaldi LME, D’Angelo SV. Brief report: autoimmune protein S deficiency in a boy with severe thromboembolic disease. N Engl J Med. 1993; 328: 1753-1757.